Challenges in the prevention of venous thromboembolism in the elderly.
Aging itself is a risk factor for venous thromboembolism, and the prevalence in the elderly of additional risk factors (e.g. cancer, orthopedic surgery, immobility) increase its intrinsic risk. Many in the medical community are reluctant to prescribe anticoagulation (for primary and secondary prevention of venous thromboembolism) to their geriatric patients for the fear that bleeding complications may outweigh the benefits. A thorough analysis of the data support the concept that the under-use of heparin in primary prevention in the elderly is more related to medical beliefs than to facts. The risk of bleeding due to oral anticoagulants (secondary prevention) is greatly reduced by keeping the International Normalized Ratio (INR) values within therapeutic ranges and carefully avoiding conditions/drugs that may interfere with such treatment. The oral direct thrombin inhibitor ximelagatran has been studied for primary (hip and knee replacement surgery) and for secondary prophylaxis of venous thromboembolism, and for acute venous thromboembolism treatment. The selective factor Xa inhibitor fondaparinux has been approved for primary prophylaxis of venous thromboembolism in hip and knee replacement surgery and in hip fracture surgery. Studies on the latter drugs, where most of the patients were > 65 years of age, further show that the fear of bleeding complications due to anticoagulation in the elderly is largely unjustified.
Di Minno
G
G
Centro di Coordinamento Regionale per le Emocoagulopatie, Dipartimento di Medicina Clinica e Sperimentale, AUP 'Federico II', Napoli, Italy.
Tufano
A
A
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000925:Anticoagulants / Q000494:pharmacology; D001384:Azetidines / Q000494:pharmacology; D001596:Benzylamines; D002986:Clinical Trials as Topic; D065427:Factor Xa Inhibitors; D000077425:Fondaparinux; D006470:Hemorrhage; D006801:Humans; D019934:International Normalized Ratio; D011134:Polysaccharides / Q000494:pharmacology; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*; D013997:Time Factors; D020246:Venous Thrombosis / Q000453:epidemiology / Q000517:prevention & control*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D065427:Factor Xa Inhibitors; D011134:Polysaccharides; C426686:ximelagatran; D000077425:Fondaparinux